|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TCEAL1 |
Gene summary for TCEAL1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TCEAL1 | Gene ID | 9338 |
| Gene name | transcription elongation factor A like 1 | |
| Gene Alias | SIIR | |
| Cytomap | Xq22.2 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q15170 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9338 | TCEAL1 | LZE4T | Human | Esophagus | ESCC | 2.24e-10 | 1.98e-01 | 0.0811 |
| 9338 | TCEAL1 | LZE7T | Human | Esophagus | ESCC | 1.99e-03 | 4.63e-01 | 0.0667 |
| 9338 | TCEAL1 | LZE20T | Human | Esophagus | ESCC | 3.18e-03 | 6.31e-02 | 0.0662 |
| 9338 | TCEAL1 | LZE22T | Human | Esophagus | ESCC | 8.21e-06 | 3.14e-01 | 0.068 |
| 9338 | TCEAL1 | LZE24T | Human | Esophagus | ESCC | 3.97e-14 | 4.16e-01 | 0.0596 |
| 9338 | TCEAL1 | P1T-E | Human | Esophagus | ESCC | 2.58e-02 | 2.47e-01 | 0.0875 |
| 9338 | TCEAL1 | P2T-E | Human | Esophagus | ESCC | 8.50e-15 | 2.18e-01 | 0.1177 |
| 9338 | TCEAL1 | P4T-E | Human | Esophagus | ESCC | 3.42e-16 | 3.19e-01 | 0.1323 |
| 9338 | TCEAL1 | P5T-E | Human | Esophagus | ESCC | 4.30e-11 | 2.54e-02 | 0.1327 |
| 9338 | TCEAL1 | P8T-E | Human | Esophagus | ESCC | 6.33e-21 | 4.14e-01 | 0.0889 |
| 9338 | TCEAL1 | P9T-E | Human | Esophagus | ESCC | 9.74e-26 | 4.96e-01 | 0.1131 |
| 9338 | TCEAL1 | P10T-E | Human | Esophagus | ESCC | 1.21e-17 | 3.94e-01 | 0.116 |
| 9338 | TCEAL1 | P11T-E | Human | Esophagus | ESCC | 1.22e-06 | 3.52e-01 | 0.1426 |
| 9338 | TCEAL1 | P12T-E | Human | Esophagus | ESCC | 6.32e-14 | 2.11e-01 | 0.1122 |
| 9338 | TCEAL1 | P15T-E | Human | Esophagus | ESCC | 2.11e-07 | 1.57e-02 | 0.1149 |
| 9338 | TCEAL1 | P16T-E | Human | Esophagus | ESCC | 1.56e-09 | 7.52e-02 | 0.1153 |
| 9338 | TCEAL1 | P17T-E | Human | Esophagus | ESCC | 2.02e-03 | 1.68e-01 | 0.1278 |
| 9338 | TCEAL1 | P19T-E | Human | Esophagus | ESCC | 1.53e-05 | 4.17e-01 | 0.1662 |
| 9338 | TCEAL1 | P20T-E | Human | Esophagus | ESCC | 2.41e-13 | 2.07e-01 | 0.1124 |
| 9338 | TCEAL1 | P21T-E | Human | Esophagus | ESCC | 2.98e-03 | 1.25e-01 | 0.1617 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TCEAL1 | SNV | Missense_Mutation | c.35N>T | p.Pro12Leu | p.P12L | Q15170 | protein_coding | deleterious_low_confidence(0) | benign(0.382) | TCGA-EK-A2RK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TCEAL1 | SNV | Missense_Mutation | c.35N>T | p.Pro12Leu | p.P12L | Q15170 | protein_coding | deleterious_low_confidence(0) | benign(0.382) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TCEAL1 | SNV | Missense_Mutation | c.35N>T | p.Pro12Leu | p.P12L | Q15170 | protein_coding | deleterious_low_confidence(0) | benign(0.382) | TCGA-A6-6650-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TCEAL1 | SNV | Missense_Mutation | novel | c.156G>T | p.Glu52Asp | p.E52D | Q15170 | protein_coding | tolerated_low_confidence(0.05) | probably_damaging(0.994) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TCEAL1 | SNV | Missense_Mutation | novel | c.467N>A | p.Pro156His | p.P156H | Q15170 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TCEAL1 | SNV | Missense_Mutation | c.244N>T | p.Arg82Cys | p.R82C | Q15170 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.992) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD | |
| TCEAL1 | SNV | Missense_Mutation | c.88N>A | p.Glu30Lys | p.E30K | Q15170 | protein_coding | tolerated_low_confidence(0.22) | benign(0.245) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| TCEAL1 | SNV | Missense_Mutation | c.306N>G | p.Phe102Leu | p.F102L | Q15170 | protein_coding | tolerated(0.22) | probably_damaging(0.99) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| TCEAL1 | SNV | Missense_Mutation | rs777155549 | c.361N>C | p.Asn121His | p.N121H | Q15170 | protein_coding | tolerated(0.63) | probably_damaging(0.998) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
| TCEAL1 | SNV | Missense_Mutation | rs1052146 | c.242N>T | p.Gly81Val | p.G81V | Q15170 | protein_coding | deleterious_low_confidence(0.04) | benign(0) | TCGA-55-8097-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |